reason report
bottom line report result yesterday market
close yesterday despit revenu declin yoy result
slightli beat consensu expect above-consensu revenu
forecast ep grew driven prior period share repurchas
question call concern compani emerg
pipelin mainli oncolog product compani upgrad
outcom one colorect cancer patient treat kra
inhibitor stabl diseas respons amgen
stock like remain somewhat range-bound near term specter
continu rapid eros growth factor brand legal
risk face enbrel act brake investor interest enthusiasm
despit pipelin potenti base quarter result
manag comment updat guidanc slightli reduc
revenu forecast increas ep forecast base continu
share repurchas price target remain reiter
yesterday market close report slight
revenu beat ep beat versu consensu slightli
increas low end full-year revenu ep
guidanc rang legaci product remain pressur
sensipar notabl weak vs consensu suggest
eros could faster current expect enbrel exceed
expect vs consensu mostli due favor
price benefit occur despit declin unit volum
manag commentari loom enbrel patent litig
littl allay concern enbrel revenu could risk pend
offer off-set eros legaci product show solid
volum growth manag commentari suggest favor
reimburs progress product
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform svb leerink llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
year price history/av daili volume mil
oncolog pipelin continu progress key program
come poc trial manag provid import
updat number close watch earli stage oncolog
develop program significantli confirm kra
inhibitor start potenti pivot monotherapi
trial advanc kra lung cancer near futur
addit compani confirm one colorect cancer
patient previous report stabl diseas becom
respond possibl respons emerg
group patient treat highest dose longer
durat also suggest half life extend hle
bispecif advanc clinic first data
program present later year potenti dec
suspend develop two cell therapi partial
basi enthusiasm bispecif
target program well other
tezepelumab asthma could gener meaning excit
investor overhang compani legal
estim modestli chang price target maintain
decreas revenu estim ep estim
increas later year mainli due
lower share count adjust revenu forecast recent
consensu year adjust ep estim
recent consensu year base
chang price target maintain reiter
market perform rate stock like enjoy brief ralli
basi singl respond like
range-bound pend resolut patent risk enbrel
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
total revenu higher estim higher
consensu result product mix affect stronger-than-expect
sale product offset eros other posit enbrel vectibix blincyto
erythropoietin result off-set acceler eros filgrastim franchis product product sale
declin yoy increas compar result also
higher consensu estim yoy total product sale volum growth
off-set price headwind product revenu driven
yoy declin due prior year mileston payment total incom expens
higher yoy due prior year invest liquid loss well
posit perform ventur portfolio
enbrel sale stronger consensu estim
yoy growth enbrel sale mainli driven increas net sell price
volum declin despit favor build-up inventori
biosimilar competit continu erod amgen us neulasta sale lead yoy
qoq eros global neulasta sale consensu eros
steeper anticip compani benefit larg
purchas us govern occur indic exit hold
share long-act market onpro command market share suggest
eros could continu even acceler later year least threshold
sensipar biggest outlier revenu final collaps face gener entri us
sale miss consensu forecast
hematology/oncolog product sale grew yoy driven unit volum growth
includ vectibix nplate xgeva kyproli blincyto
imlyg report
recent launch product mix repatha miss consensu estim
despit us volum growth off-set declin net sell price aimovig sale
in-lin consensu estim commentari
suggest continu segment leadership paid prescript increas sequenti
versu even growth repres recent launch sale easili
beat consensu estim
gross margin slightli higher consensu estim line
estim margin lower prior period like due continu price pressur
legaci portfolio expens grew yoy sequenti larg
attribut advanc early- late-stag oncolog asset sg expens
increas year ago support end certain acquisition-rel intang asset
amort charg repres total product sale oper margin
declin last year due increas spend pipelin asset
tax rate increas yoy due prior year tax benefit associ inter-company
sale us corpor tax reform non-gaap net incom
consensu estim deploy repurchas
share averag price per share report averag dilut
share count lower consensu lower yoy basi
result non-gaap ep came repres growth yoy beat consensu
quarter increas lower end revenu ep guidanc rang
compani expect revenu non-gaap ep
consensu revenu midpoint
guidanc rang consensu non-gaap ep midpoint guidanc
rang reiter tax guidanc capit expenditur
also announc intent repurchas increment compani
stock presum alreadi incorpor updat guidanc
furthermor manag continu expect oper expens remain flat absolut
basi versu although margin remain depress increment lower
continu momentum oncolog pipelin late-stag asset
invest heavili wide rang new oncolog target modal
bispecif t-cell engag bite project begin produc meaning earli
clinic data present data multipl early-stag oncolog asset
american societi clinic oncolog meet includ kra
inhibitor psma bite bcma bite
continu believ promis excit asset
inhibitor mutat kra occur adenocarcinoma
wide rang solid tumor includ pancreat cancer colorect cancer current
phase clinic trial patient solid tumor kra
mutat saw encourag earli data respons rate observ
nsclc see note confer call manag indic
seen confirm tumor respons one colorect cancer one appendic cancer
patient surpris given multipl case stabl diseas previous report
lower dose expect present provid updat nsclc includ durabl
data world lung confer septemb thu far manag seen
signific data suggest emerg resist remain optimist
prospect combin inhibitor achiev durabl respons expect
updat later year earli next year addit data accumul
manag continu optimist promis hle portfolio bite asset
hle version advanc dose escal initi first-in-
human data expect next spring could support posit manag commentari around
next-gener bispecif
later-stag asset includ omecamtiv mecarbil hfref enrol complet
exceed patient phase asthma studi tezepelumab continu
schedul posit data could provid signific upsid asset larg
overhang continu detract promis pipelin
continu believ potenti near-term outcom on-going enbrel litig
present signific overhang stock caus mani investor stay sidelin
believ neg outcom fulli incorpor consensu sell-sid
investor expect moreov on-going price reform eman washington
creat addit overhang view specter price control scare
investor believ resolut overhang could allow investor shift focu
toward promis grow pipelin expect multipl data updat
kra inhibitor second half extend result nsclc monotherapi
updat result solid tumor cohort compani also indic
initi potenti registr monotherapi studi year
also broad portfolio bispecif antibodi target hematolog malign solid
tumor molecul still preclin early-stag clinic develop later
year await data two inhibitor phase
clinic trial acut myeloid leukemia aml multipl myeloma mm broad rang
modest model updat slower launch eros pt maintain
base quarter result manag comment guidanc decreas
revenu estim ep estim increas
later year mainli due lower share count adjust revenu forecast
recent consensu year adjust ep estim
recent consensu year base chang price target
maintain reiter market perform rate stock like enjoy
brief ralli basi singl respond like range-
bound pend resolut patent risk enbrel
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock
sni rhhbi gsk nv celg price sale multipl larg cap
biotechnolog pharma compani novo nv celg
discount cash flow dcf use rel multipl larg cap biopharma
compani ep appli ep estim
give one year futur valu use establish larg cap futur revenu multipl
sale appli revenu forecast give futur
valu final dcf valuat base current outlook compani
exist product probability-weight revenu contribut late-stag pipelin
program discount compani wacc give fair valu today
averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
expect
extend result nsclc monotherapi cohort
updat result solid tumor
phase studi remicad biosimilar
phase studi rituxan biosimilar
initi potenti registr
decis district court nj sandoz vs
phase candor trial combin
darzalex dexamethason
svb leerink llc research compani file
million
corp partner revenue incl royalti
po probabl success fda approv
sbv leerink llc research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
sbv leerink llc research compani file
analysi stock price svb leerink target
method model larg cap healthcar growth stock ep multipl ep
appli amgen ep
svb leerink updat ep estim
current averag ep multipl consensu ep compar
slow grow us eu larg cap biopharma stock
impli target price ep
celg revenu multipl appli svb leerink
svb leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma comp
method dcf adjust debt declin flow
stabl termin cash flow growth discount wacc
present valu flow termin valu
averag method
svb leerink llc research compani file factset
